Oncology: International Journal of Cancer Research and Treatment
Published online: January 2018
DOI: https://doi.org/10.1159/000485562
Schwab K.S.a · Kristiansen G.b · Schild H.H.c · Held S.E.A.a · Heine A.a · Brossart P.a
Background: Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.